Form 4: Contineum Therapeutics CFO Peter Slover Granted 100,000 Stock Options

Contineum Therapeutics' Chief Financial Officer, Peter Slover, was granted 100,000 stock options on May 24, 2024, under the company's 2024 Equity Incentive Plan.

Summary

• Peter Slover, the Chief Financial Officer of Contineum Therapeutics, Inc., was granted 100,000 stock options on May 24, 2024.
• The options were granted under the Issuer's 2024 Equity Incentive Plan.
• The exercise price of the options is $15.76.
• 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The grant incentivizes the CFO, which is generally viewed favorably.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment and performance from the CFO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to align executive incentives with shareholder value.
• The vesting schedule of 25% after one year followed by monthly installments is also a typical arrangement.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates